Tocilizumab and its usage for skin diseases

Area of Science:

• Immunodermatology
• Rheumatology
• Pharmacology

Background:

• Tocilizumab, a monoclonal anti-IL6 receptor antibody, is established in rheumatology for joint diseases.
• Its dermatological applications are emerging, primarily for scleroderma and Systemic Sclerosis.

Purpose of the Study:

• To review the current evidence on Tocilizumab's use in diverse dermatological conditions.
• To highlight its efficacy, side effects, and potential therapeutic roles in skin diseases.
• To stimulate further research and explore future treatment options.

Main Methods:

• Literature review of studies on Tocilizumab in dermatology.
• Analysis of its application in conditions like psoriasis, Behcet's Syndrome, Lupus, and scleroderma.
• Examination of reported cutaneous side effects and management strategies.

Main Results:

• Tocilizumab has been used off-label for various skin conditions including psoriasis, psoriatic arthritis, Behcet's Syndrome, Lupus, and scleroderma.
• Cutaneous side effects necessitate vigilant monitoring during Tocilizumab therapy.
• Evidence suggests potential benefits but lacks formal therapeutic recommendations for these dermatoses.

Conclusions:

• Tocilizumab presents a potential therapeutic avenue for several dermatological conditions.
• Further research is warranted to establish formal guidelines for its use in dermatology.
• Careful patient selection and monitoring are essential due to associated skin reactions.